RGNX (Regenxbio) Short Percentage of Float


RGNX Regenxbio Inc RGNX
60 GF Score
Price $13.09
GF Value $14.07
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Regenxbio Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RGNX vs ALT, ASMB, CTNM: Short Percentage of Float Comparison

For the Biotechnology subindustry, Regenxbio's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenxbio Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Regenxbio's Short Percentage of Float falls into.


RGNX
60GF Score
Regenxbio Inc RGNX
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Regenxbio (RGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be undervalued. The current stock price of $13.09 is trading 7% below its estimated GF Value™ of $14.07. GuruFocus considers Regenxbio to be Fairly Valued.

Key valuation signals for RGNX:

  • Short Percentage of Float:
  • GF Value™: $14.07 vs. price of $13.09 (7% below fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the RGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regenxbio Business Description

Other Exchanges RB0:Germany
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
60GF Score

Get the complete analysis for RGNX

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.09
Price
$14.07
GF Value